E-Scape Bio, a spinout of Gladstone Institutes, has achieved a final close of its series A thanks to commitments from Osage University Partners and several corporates.

The immune system-based cybersecurity software spinout based on University of Cambridge research has now raised about $180m in total.

LogicBio is developing treatments for orphan paediatric diseases, based on research conducted at Tel Aviv University, Stanford University and Children's Medical Research Institute.

Repare Therapeutics was co-founded by researchers from Lunenfeld-Tanenbaum Research Institute, University of Toronto and New York University.

Universities-backed online education provider Coursera is reportedly valued at $800m after closing a series D round that will support its new enterprise-focused product.

Novartis and GlaxoSmithKline have returned to back a series B round that also attracted Singapore state-backed Vertex Ventures and university venturing fund Cambridge Innovation Capital.

Sosei will pay $45m for a 25% stake in RNA therapy developer Mina Therapeutics and could buy the NTNU spinout outright for about $180m more.

Exploiting research conducted at Navarra University and Harvard Medical School, Vivet Therapeutics is working on gene therapies for metabolic diseases.

Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.